Neoadjuvant nivolumab treatment improves survival rates in N

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

Related Keywords

United States , America , American , Samuel Rosner , Patrick Forde , Bristol Myers Squibb , Emily Henderson , Cancer Research Industry , National Institutes Of Health , Johns Hopkins University Cancer Center , Cancer Foundation , Lung Cancer Foundation Of America , Cancer Research Group , Cancer Research , Macmillan Foundation , Lungevity Foundation , American Association For Cancer Research , Thoracic Oncology Clinical Research Program , International Immuno , Oncology Network , Memorial Sloan Kettering Cancer Center , Clinical Cancer Research , American Association , Sidney Kimmel Comprehensive Cancer Center , Johns Hopkins , Research Industry Focus , Drug Administration , Stand Up To Cancer , Scientific Partner , International Immuno Oncology Network , International Association , Lung Cancer , Prevent Cancer Foundation , Lung Cancer Foundation , Research Group , National Institutes , Memorial Sloan Kettering Cancer , Cancer , Fell , Non Small Cell Lung Cancer , Small Cell Lung Cancer , Biomarker , Chemotherapy , Efficacy , Mesothelioma , Ncology , Pd L1 , Pharmaceuticals , Research , Surgery , Herapeutics , Humor ,